EACS2023: 675 HIV-2 in Germany: an observational study on the situation of people living with HIV-2 infection (PLHIV2) in Germany (“H2O”) D. Berzow , R.L. Scheiter , O. Degen , G. Schäfer , T. Buhk , C. Hoffmann , K. Cron , A. Stoehr , H. Metthews , M. Almahfoud , J. Schulze zur Wiesch , R. Kaiser , M. Obermeyer Praxis for Infectiology, Hamburg, Germany, University Medical Centre, Department for Infectiology, Hamburg, Germany, ICH Medical Care Centre, Hamburg, Germany, IFI Institute for Interdisciplinary Medicine, Hamburg, Germany, University Medical Centre, Internal Medicine and Clinical Immunology, Hamburg, Germany, DZIF, Hamburg, Germany, University of Cologne, Institute of Virology, Köln, Germany, HIVGRADE, Berlin, Germany, mib, Berlin, Germany General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: HIV-2 infection differs from HIV-1 infection in its clinical course (RNA levels, loss of CD4+ cells, disease progression) and treatment strategies (choice of antiretroviral agents, initiation of treatment, markers of success). But unfortunately, there is much less data on HIV-2. Method: We initiated a retro- and prospective observational cohort study of patients living with HIV-2 infection in 2021 (“H2O”). Results: At the time of this preliminary analysis (June 2023), 18 individuals were included. The observation period was 233 patient years, 114 without ART and 119 under ART. There were 16 clinical events, 8 involved the gastrointestinal tract. 5/18 patients (28%) showed no disease progression (“non-progression”, 66 py) and stable CD4 cell counts without ART. Nevertheless 3/5 were viraemic at least at one point in time. 13/18 (72%) showed progression (clinical events, CD4 cell loss, repeatedly viraemia) and received therapy (167 py). 11/13 were considered to have been successfully treated. 4 started ART before 2011. 2 were almost always viraemic, acquired multi-class resistance, CD4-T-cell exhaustion and AIDS-defining events under ART. 9 patients started after 2011 (7/9 INI, 2/9 PI). Of these, 3/9 started ART at time of diagnosis.The median CD4 cell gain was +114 and +112 c/µl after 12 and 24 month, respectively. All were viremic at least at one point in time. 6/9 started ART during the observation time. The median CD4 cell count gain was +71 and +179 c/µl, after 12 and 24 month, respectively. 4/6 were viremic after start at least at one point in time, but remained on same treatment. Conclusions: In this small cohort, 13/18 of the participants showed progression. 2 participants who started ART before 2011 (n=4) showed a problematic progression. The 9/18 participants who started ART after 2011 showed a satisfactory outcome. The role of plasma RNA in HIV-2 monitoring remains debatable. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 2 3 3 3 4 4 2 2 5,6 7,8 9,8 1 2 3 4 5 6 7 8 9 147
RkJQdWJsaXNoZXIy Mzc2ODc=